Amgen's less frequent dosing weight-loss drug presents a growing challenge for LLY in the long term, however the article on 'unstoppable stocks' suggests strong fundamentals can sustain the price near term. A price target adjustment is warranted based on sustained growth projections despite the emergence of competitors.

Despite some negative headlines around sector softness and FDA delays, the 'unstoppable stocks' article and positive weight-loss drug news are likely to boost market sentiment towards LLY. Overall market sentiment seems mixed, requiring careful monitoring.

While LLY faces long-term competition in the weight-loss drug market and regulatory hurdles, the overall healthcare sector demonstrates resilience. Considering State Street's growing crypto presence, diversification across sectors could provide a hedge against potential market volatility.

Despite sector softness updates, LLY is featured in an 'unstoppable stocks' list, signaling potential bullish continuation patterns in price and volume. A delayed GLP-1 review introduces slight ambiguity, necessitating further data assessment, but the momentum appears positive.